Felli, Eric; Nulan, Yeliduosi; Selicean, Sonia; Wang, Cong; Gracia-Sancho, Jordi; Bosch, Jaume (2023). Emerging Therapeutic Targets for Portal Hypertension. Current hepatology reports, 22(1), pp. 51-66. Springer 10.1007/s11901-023-00598-4
|
Text
s11901-023-00598-4-1.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (1MB) | Preview |
PURPOSE OF REVIEW
Portal hypertension is responsible of the main complications of cirrhosis, which carries a high mortality. Recent treatments have improved prognosis, but this is still far from ideal. This paper reviews new potential therapeutic targets unveiled by advances of key pathophysiologic processes.
RECENT FINDINGS
Recent research highlighted the importance of suppressing etiologic factors and a safe lifestyle and outlined new mechanisms modulating portal pressure. These include intrahepatic abnormalities linked to inflammation, fibrogenesis, vascular occlusion, parenchymal extinction, and angiogenesis; impaired regeneration; increased hepatic vascular tone due to sinusoidal endothelial dysfunction with insufficient NO availability; and paracrine liver cell crosstalk. Moreover, pathways such as the gut-liver axis modulate splanchnic vasodilatation and systemic inflammation, exacerbate liver fibrosis, and are being targeted by therapy. We have summarized studies of new agents addressing these targets.
SUMMARY
New agents, alone or in combination, allow acting in complementary mechanisms offering a more profound effect on portal hypertension while simultaneously limiting disease progression and favoring regression of fibrosis and of cirrhosis. Major changes in treatment paradigms are anticipated.
Actions (login required)
 |
Edit item |